

Dec 27, 2021

Whom It May Concern

Company: KYORIN Holdings, Inc.
Representative: Yutaka Ogihara
Representative Director, President
(Security Code: 4569, TSE 1st Sec.)
Contact: Yoshinori Tanifuji
Director, Management Strategy &
Planning Division Corporate Planning
Telephone: +81-3-3525-4707

Kyorin Signed Memorandum of Understanding on Co-Promotion of “Lagevrio® Capsule 200mg” for COVID-19 Treatment

KYORIN Pharmaceutical Co., Ltd. (Head office: Chiyoda-ku, Tokyo, President & CEO: Shigeru Ogihara, "KYORIN Pharmaceutical"), a subsidiary of KYORIN Holdings, Inc., signed a Memorandum of Understanding regard a negotiation right toward local Co-Promotion collaboration of “Lagevrio® Capsule 200mg” (Molnupiravir) an oral antiviral COVID-19 treatment for which MSD K.K. (Head office: Chiyoda-ku, Tokyo, President: Kyle Tattle, “MSD”) received its manufacturing and marketing approval.

Under the Memorandum, KYORIN Pharmaceutical will negotiate with MSD on the contract for Co-Promotion collaboration of “Lagevrio®” in Japan.

“Lagevrio®” is a potent ribonucleoside analog medicine that can be orally administered and inhibits the replication of SARS-CoV-2, the causative agent of COVID-19. Based on the results of the interim analysis of the Phase 3 study (MOVE-OUT study) targeting mild to moderate adult patients with one or more risk factors such as obesity, advanced age, diabetes etc., MSD requested the application of special approval for emergency and obtained manufacturing and marketing approval.

KYORIN Pharmaceutical will continue to work on increasing presence in its strategic fields of respiratory and ear-nose-throat and contributing to the treatment of COVID-19.

The impact of the Memorandum on KYORIN Holdings’ consolidated operating results for the fiscal year ending March 31, 2022 will be announced as soon as it is finalized.